IGF2BP1 and neoplasm: Like observed for BRDi, IGF2BP1-KO reduced EC50 values (~ threefold) for BIRC5i by YM-155 (Fig. 5d), which was well tolerated in clinical trials and showed anti-tumor activity in combination therapy [26, 64, 65].